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Abstract
To investigate further the antiangiogenic potential of sunitinib for renal cell carcinoma (RCC) treatment, its effects
on tumor vasculature were monitored by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using
an orthotopic KCI-18 model of human RCC xenografts in nude mice. Tumor-bearing mice were treated with various
doses of sunitinib, and vascular changes were assessed by DCE-MRI and histologic studies. Sunitinib induced dose-
dependent vascular changes, which were observed both in kidney tumors and in normal kidneys by DCE-MRI. A dos-
age of 10 mg/kg per day caused mild changes in Gd uptake and clearance kinetics in kidney tumors. A dosage of
40 mg/kg per day induced increased vascular tumor permeability with Gd retention, probably resulting from the de-
struction of tumor vasculature, and also caused vascular alterations of normal vessels. However, sunitinib at 20mg/kg
per day caused increased tumor perfusion and decreased vascular permeability associated with thinning and regulari-
zation of tumor vesselswhilemildly affecting normal vessels as confirmed by histologic diagnosis. Alterations in tumor
vasculature resulted in a significant inhibition of KCI-18 RCC tumor growth at sunitinib dosages of 20 and 40mg/kg per
day. Sunitinib also exerted a direct cytotoxic effect in KCI-18 cells in vitro. KCI-18 cells and tumors expressed vascular
endothelial growth factor receptor 2 and platelet-derived growth factor receptor β molecular targets of sunitinib that
weremodulated by the drug treatment. These data suggest that a sunitinib dosage of 20mg/kg per day, which inhibits
RCC tumor growth and regularizes tumor vessels with milder effects on normal vessels, could be used to improve
blood flow for combinationwith chemotherapy. These studies emphasize the clinical potential of DCE-MRI in selecting
the dose and schedule of antiangiogenic compounds.
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Introduction
Renal cell carcinoma (RCC) incidence has increased in recent years
with approximately 54,390 new cases each year in the United States.
The disease is responsible for an estimated 13,010 deaths each year
[1]. Nearly half of the patients present with localized disease that can
be treated by surgical removal [2,3]. However, one third of the patients
have metastatic disease at first presentation, and 20% to 30% of the pa-
tients treated for localized RCC subsequently develop metastatic disease
that frequently involves the lungs [2,3]. The median survival of patients
withmetastatic RCC ranged from 8 to 11months [2–4]. The treatment
of metastatic RCC remains a significant challenge, but recent develop-
ments in antiangiogenic therapy have improved targeting these highly
vascularized tumors.
The vascular endothelial growth factor (VEGF), produced by tumor
cells and associated stromal cells, is a key growth factor in the angiogenic
process, which promotes the proliferation, migration, and invasion of
endothelial cells and plays a role in vascular permeability [5]. Targeting
the tumor vasculature with antiangiogenic therapy has been shown to
suppress the growth of established tumors in mice, leading to several
clinical trials with different angiogenesis inhibitors [5,6]. Numerous
antiangiogenic compounds recently developed include anti-VEGF anti-
bodies and inhibitors of receptor tyrosine kinases (RTKs). The drug
sunitinib (SU11248 or Sutent) is a small-molecule RTK inhibitor that
has demonstrated antitumor and antiangiogenic activities in mouse
xenograft models. Sunitinib targets and inhibits signaling of several
RTKs including platelet-derived growth factor receptor (PDGFR),
VEGF receptor (VEGFR), c-kit protooncogene, and FMS-like tyrosine
kinase 3 [7–13]. Sunitinib exhibits direct antitumor activity by inhibit-
ing RTKs that are expressed by cancer cells and are involved in signaling
for cancer cell proliferation [7]. Sunitinib also exhibits antiangiogenic
activity by inhibition of signaling through VEGFR-2 and PDGFR-β
RTKs expressed on endothelial cells or stromal cells [7]. Initial clinical
trials with sunitinib for metastatic RCC showed significant responses in
multiple metastatic sites and in primary tumors resulting in 40% partial
response rate with a median time to progression of 8.7 months [14].
These studies justified approval of sunitinib by the FDA in January
2006 for RCC treatment. In a phase 3 multinational study of 750 pa-
tients withmetastatic RCC, randomized to sunitinib or interferonα, the
response rate to sunitinib was 31%, with median progression-free sur-
vival (PFS) of 11.7 months and a median survival of 28 months [15]. A
recent update of this trial documented an objective response rate of 47%
with 11 months of median PFS for sunitinib versus 12% objective re-
sponse rate and 5 months of PFS for interferon α [16]. Although the
results with sunitinib therapy are impressive, long-term control of the
disease is still not achieved. In addition, several trials documented ad-
verse effects of cardiotoxicity in some of the patients, probably as a result
of alterations to normal vasculature [17–20]. Therefore, further investi-
gations with sunitinib dose adjustments are warranted to decrease the
impact on vital organs such as the heart and the kidney.
The goal of our study was to investigate the effect of lower and
potentially less toxic doses of sunitinib on tumor vasculature to establish
the conditions for combination therapies to determine whether a com-
bined strategy could maintain and improve efficacy. Disruption of the
tumor vasculature to deprive tumor cells from nutrients by sunitinib,
given in conjunction with cytotoxic therapies, could be more effective
in preventing progression of metastatic RCC. However, this approach
could be a paradox given that complete destruction of tumor vasculature
could compromise the efficacy of chemotherapy or radiotherapy because
both depend on blood flow to the tumor for delivering oxygen and
drugs [21,22]. To improve the blood flow in tumors, the concept of
“normalization” of tumor vasculature is based on the regularization
of tumor vessels by pruning or destroying immature and inefficient
blood vessels through elimination of excess endothelial cells, and it
has shown promise for combination therapies [23–27]. The process
of tumor angiogenesis involves proliferation of abnormal vessels that
are enlarged, disorganized, and leaky due to the defective basement
membrane. These structural defects of tumor vessels cause increased
interstitial tissue pressure, impaired blood supply, and decreased oxy-
gen supply in tumors compromising the delivery and efficacy of cyto-
toxic drugs and radiotherapy [21,22]. The challenge is to develop
imaging technologies that monitor early vascular changes and induc-
tion of tumor vasculature normalization by antiangiogenic drugs for
scheduling cytotoxic therapy.
We selected to use dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI) to investigate the effect of sunitinib therapy on
RCC tumor vasculature using a preclinical papillary RCC murine
model. DCE-MRI is a noninvasive approach, currently used in humans,
that can detect early changes in the tumor induced by antiangiogenic
therapy as reported in human studies [28–31] and in preclinical animal
models [32,33]. This method measures a combination of tumor per-
fusion and vessel permeability and allows the detection of changes in
tumor vascularity, which occur at a much earlier stage in the treatment
of tumors with antiangiogenic drugs than does shrinkage of tumor mass
[29,31]. Contrast agents typically consist of gadolinium (Gd)-based
chelates with paramagnetic properties that are used to enhance signal
from the tissue in clinical MRI. The contrast agent, injected intrave-
nously, enters the extravascular extracellular space through the capillary
bed as a function of perfusion and permeability. The contrast agent that
accumulates over time in the tumor can be then analyzed by MRI
[29,31]. Recent animal studies suggest that parametric images providing
information on the morphology and function of the microvasculature
of tumors can be obtained by Gd-DTPA–based DCE-MRI [34].
DCE-MRI was performed using an orthotopic RCC model in
athymic nude mice, which was established by subcapsular renal im-
plantation of Karmanos Cancer Institute-18 (KCI-18) cells, a tumor
cell line generated from a human papillary RCC specimen in our labo-
ratory [35]. Vascular changes induced by various doses of sunitinib in
tumor-bearing kidneys and normal contralateral kidneys were moni-
tored by DCE-MRI and by histologic studies of tissue sections.
Materials and Methods
Orthotopic KCI-18/IK RCC Tumor Model
The human RCC cell line designated KCI-18 was established in our
laboratory from a primary renal tumor specimen obtained from a
patient with papillary RCC (nuclear grade 3/4) [35]. Cells were cul-
tured in Dulbecco’s modified Eagle medium with supplements [35].
After serial passages of KCI-18 cells in the kidney of nude mice, highly
tumorigenic KCI-18/IK were generated [35]. KCI-18/IK cells were
washed with Hank’s balanced salt solution and subcapsularly injected
at a concentration of 5 × 105 cells in 30 μl of Hank’s balanced salt
solution in the right kidney in 5- to 6-week-old female BALB/C nu/nu
nude mice (Harlan, Indianapolis, IN) [35]. Mice were housed and
handled under sterile conditions in facilities accredited by the American
Association for the Accreditation of Laboratory Animal Care. The animal
protocol was approved by the Animal Investigation Committee of
Wayne State University.
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Experimental Protocol
After injection of KCI-18/IK cells, a fewmice were killed at early time
points to assess tumor growth before initiating treatment. Small tumors
were detectable by days 9 to 10 in the kidney. By days 10 to 12, mice
bearing established kidney tumors (KTs) were treated with sunitinib
(Pfizer, Inc, New York, NY). The drug was prepared in a carboxymethyl
cellulose suspension vehicle, at dosages of 10, 20, or 40 mg/kg per day
(SU10, SU20, or SU40, respectively) and given orally by gavage, once
a day [7]. Control mice were treated with vehicle only. Treatment was
continued for 7 to 18 days. On the basis of initial experiments, early
time points of 7-day sunitinib treatment were selected for DCE-MRI
studies or for monitoring RTKs expression to avoid incorrect analysis
of advanced and large necrotic tumors in control mice. For DCE-MRI
experiments, three mice per treatment group were imaged. To assess the
therapeutic response of KTs to an optimal dosage of 40 mg/kg per day
of sunitinib, 10 mice per experimental group were treated daily for
18 days. For sunitinib dose-response studies, eight mice per experi-
mental group were treated daily with 10, 20 or 40 mg/kg per day of
sunitinib. Mice were killed by day 28 after tumor cell injection, when
the tumor burden in control animals was large (>1.5 cm × 1 cm in size
compared with 0.7 cm × 0.25 cm for normal kidney [NK]) to compare
with tumor sizes in treated groups. Tumor-bearing kidneys were resected
and weighed [35].
Tissue Preparation for Histologic Diagnosis
At completion of experiments, mice were killed and KTs as well
as the contralateral NKs were resected and processed for histologic
diagnosis. All tissues were fixed in 10% buffered formalin, embedded
in paraffin, and sectioned [35]. Sections were stained with hematoxylin-
eosin (H&E) [35]. Tissue sections were also immunostained with
anti-CD31 antibody (Ab; Thermo Scientific, Fremont, CA) using an
avidin-biotin immunoperoxidase technique [35].
DCE-MRI Monitoring of Tumor Perfusion and
Permeability and Tumor Size in KTs
Mice from control and sunitinib-treated groups were imaged by
DCE-MRI. Mice were anesthetized by intraperitoneal injections of
0.35 ml of pentobarbital and 0.35 ml of ketamine at a concentration
of 52.5 mg/kg then a catheter was inserted into their tail vein, which
was attached to a syringe containing Gd-DTPA contrast agent (Berlex,
Wayne, NJ). Mice were positioned on a cradle heated by temperature-
controlled water and were given a second low dose of anesthetics of
15 mg/kg each in 0.1 ml to avoid motion problems while in the
magnet. A 2-cm-diameter receive-only surface coil was placed over
the tumor, and the cradle was placed inside an 11-cm inner-diameter
transmit-only volume coil. DCE-MRI of mice was performed in the
MR Research Facility at Wayne State University using a Bruker Biospec
AVANCE animal scanner (Bruker, Karlsruhe, Germany) equipped
with a 4.7-T horizontal bore magnet and actively shielded gradients.
Anatomic imaging was done using a two-dimensional T2-weighted
spin-echo scan (repetition time = 2000 milliseconds, echo time =
52.4 milliseconds) to get an overview of the kidney. Baseline imaging
data of the kidneys were obtained using the short-repetition time DCE
scan for 30 time points (7 seconds between time points). On time
point 10, 100 μl of Gd-DTPA (0.125 mmol/kg) was injected into
the tail vein catheter. This dose was selected based on preliminary
Gd dose-searching experiments to obtain appropriate contrast for
image analysis. Then, imaging data were acquired for 20 more time
points. The imaging parameters for this multislice two-dimensional
gradient echo scan were as follows: repetition time = 54.7milliseconds,
echo time = 2.9 milliseconds, flip angle = 30 degrees, field of view =
32 mm × 32 mm, slice thickness = 1.5 mm with 0.5-mm gap, matrix
size = 128 × 128. Five slices were collected for each animal. Data were
processed to determine changes in contrast agent uptake using the SPIN
DCE software (Detroit, MI) [36]. For data analysis, the full kidney was
selected as the region of interest (ROI) for the KTand the contralateral
left NK. A threshold was selected to remove noise-only pixels in the im-
age. Gd concentrations [C(t)] in the tissue were calculated for all pixels
in the ROI and for each time point [36]. Data from theC(t) curves were
compiled for each pixel for 16 time points (112 seconds) after Gd injec-
tion to create the initial area under the curve (IAUC). The distribution
of IAUC for the entire ROI is then shown as a means to visualize the
effects in every pixel in a single plot. The CIAUC is the cumulative
initial area under the curve of the IAUC histogram. For quantitative
analysis of vascular permeability, R50 (median) values are derived
from CIAUC curves and correspond to the concentration of Gd at
which 50% of the pixels have been included [36]. To evaluate the ki-
netics of uptake, washout, and leakage into the kidney tissue and tumor,
the parametric color maps are used to show the initial rate of uptake,
peak concentration and clearance of Gd in the tissue, and individual
structures in each slice. The parameters measured in DCE-MRI for
sunitinib-treated tumors were compared with those obtained for control
tumors and NKs.
Analysis of Cell Survival by Clonogenic Assay
KCI-18 cells were treated with sunitinib doses of 0.1 to 5 μM and
plated in a colony formation assay, in triplicate wells of six-well plates
at 500 cells per well for control and 0.1 μM sunitinib, at 1000 cells per
well for 0.5 and 1 μM sunitinib, and at 3000 cells per well for 2.5 and
5 μM sunitinib [37]. After 10 days of incubation at 37°C in a 5%CO2/
5% O2/90% N2 incubator, colonies were counted, the plating effi-
ciency was calculated for each well, and the surviving fraction was
normalized to control cells [37].
Expression of VEGFR-2 and PDGFR-β on
KCI-18 Cells and KCI-18 KTs
KCI-18 RCC cells, cultured in flasks, were harvested and processed
for lysis and protein extraction [37]. To detect the expression of
VEGFR-2 and PDGFR-β, cell protein extracts were first immuno-
precipitated, overnight at 4°C, with specific Abs directed against
VEGFR-2 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) and
PDGFR-β (Millipore, Temecula, CA). Immune complexes were sepa-
rated using protein A agarose beads (Millipore) [7,9], and receptor
expressions were determined by Western blot analysis using 8% SDS-
PAGE gels. KTs were snap-frozen in liquid N2. Tumors (100 mg) were
lysed for protein extraction using HNTG lysis buffer containing pro-
tease inhibitors before Western blot analysis [7,9].
Statistical Analysis
Evaluation of the shape of the frequency distribution of tumor
weights indicated that a log transformation was required to meet the as-
sumptions of normal theory tests. Two-sample t-tests were used to assess
the significance of differences in tumor weight between mice treated
with SU40 and control mice. A linear model with indicator variables
to parameterize dose was used to investigate the relationship of vehicle,
SU dose, and tumor weight. The paired difference in weight between
the NK and KTwas calculated and compared between experimental
groups. Adjustment for multiple comparisons between treatments was
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made using Holm’s [38] procedure to protect against inflated type I
errors [37].
Results
DCE-MRI of KTs
To investigate the effect of sunitinib on tumor vasculature, mice-
bearing KTs were imaged by MRI before and after contrast Gd injec-
tion. We report the data of a representative experiment comparing three
dosages of sunitinib, namely, 10, 20, and 40 mg/kg per day, to control
mice treated with vehicle. These sunitinib dosages were selected based
on previous animal studies demonstrating that 40 mg/kg per day of
sunitinib, given daily, is a biologically active dosage [7].
For data analysis, the full kidney was selected as the ROI both
for the right KT and the left NK (Figure 1A, T1). Gd concentrations
[C (t)] were calculated for all pixels in each ROI and for each time
point, and the average C (t) over all pixels was plotted (Figure 1B)
[36]. C (t) values, obtained after Gd injection, were integrated during
16 time points (112 seconds) to create the IAUC112 histograms (Fig-
ure 1C ) and CIAUC (Figure 1D). In control mice, Gd uptake was
rapid in both the KT and NK. However, the kinetics of clearance of
Gd in the KT were slow compared with faster clearance in the NK
(C (t) in Figure 1B). Indeed, the IAUC/CIAUC curves for the KT
showed a pronounced shift to the right compared with NK, indicative
of a greater retention of Gd (Figure 1, C and D). DCE-MRI of mice
treated with SU40 revealed a pattern of Gd uptake that remained at a
Figure 1. DCE-MRI of KCI-18 KTs. Mice bearing established tumors in the right kidneys were treated every day for 7 days with vehicle
only (control) or with sunitinib at dosages of 40, 20, or 10 mg/kg per day (SU40, SU20, or SU10, respectively). Then, mice were imaged
by DCE-MRI for 30 time points at 7-second intervals. (A) Baseline images were collected for the first during 10 time points before Gd
contrast agent injection. At time point 10, Gd was injected in the tail vein, and images were collected for 20 more time points. For data
analysis, the full kidney was selected as the ROI for the KT (blue contour on left of T1 image) and the contralateral left NK (red contour on
right of T1 image). A threshold was selected to remove noise only pixels in the image. (B) The kinetics of Gd contrast uptake are represented
in C (t) curves. (C) Data from the C (t) curves were compiled for 16 time points (112 seconds) after Gd injection to draw IAUC112. The small
black bar indicates the peak position of NK in control mice and can be used as a reference for curve shifting in NKs and KTs treated with
sunitinib. (D) The CIAUC graphs were derived from IAUC curves. In panels B, C, and D, blue lines are for KTs and pink lines are for NKs. Data
from a representative mouse from each treatment group are presented.
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plateau with more retention of Gd in both kidneys compared with
control mice. Retention of Gd was still greater in the KT treated with
sunitinib than in the NK as observed by a shift to the right in IAUC/
CIAUC curves relative to NK, but this shift was less pronounced than
in control tumors (Figure 1, C andD). In mice treated with SU20, pat-
terns of Gd uptake and clearance were identical in the KTand the NK
(Figure 1B). SU20mice had IAUC and CIAUC overlapping with those
of theNK, indicative of improved tumor perfusion (Figure 1,C andD).
Interestingly, the KT IAUC curve looked more regular and shifted to
the left compared with KTs in control or SU40-treated mice, indicating
decreased Gd retention. SU10 also seemed to change the kinetics of
uptake and clearance in KTs, showing a shift to the left in IAUC curves
compared with control or SU40-treated mice but less than with SU20-
treated tumors (Figure 1, C and D). In the NK, SU10 caused milder
changes in Gd uptake and clearance than SU20 or SU40 and resulted
in an IAUCpattern comparable to that of NK in control mice (Figure 1,
C and D). It should be noted that compared with tumors from con-
trol mice, sunitinib treatment at all tested dosages caused significant
shifts to the left of IAUC curves of KTs, which were more pronounced
with lower SU20 and SU10 doses than with a higher SU40 dose (as
visualized relative to the black bar on top of each graph in Figure 1C ).
Vascular changes in NKs were observed with higher SU20 and SU40
dosages and were expressed by a shift to the right in IAUC curves com-
paredwithNKs of controlmice. These data presented for onemouse per
treatment group were consistently observed for two additional mice per
group in the same experiment showing reproducibility of our findings.
To compare the patterns of Gd uptake in KTs versusNKs, R50 values
for three mice per treatment group were derived from CIAUC curves
for both KTs and NKs (Figure 2). The R50 (median) values correspond
to the concentration of Gd at which 50% of the pixels have been in-
cluded (Figure 2A) [36]. A trend in lower R50 values was observed
in SU10- and SU20-treated mice compared with control mice and
SU40-treated mice for both R50 of KTs (Figure 2B) and NKs
(Figure 2C ). R50 values of KTs were then normalized to the R50 values
of contralateral NKs for each mouse and shown as normalized R50
values (NR50) for three mice per group (Figure 2D) [36]. We found
Figure 2. R50 quantitation of DCE-MRI data of KCI-18 KTs. (A) The R50 value is derived from CIAUC curves (as shown for control mouse)
and corresponds to the Gd concentration at which 50% of the pixels have been included. (B) R50 of KTs from three mice per treatment
group. (C) R50 of contralateral NK from the same three mice per treatment group shown in panel B. (D) NR50 of KT versus NK: NR50
represents normalization of R50 values of KTs relative to R50 values of contralateral NK calculated as [R50KT − R50NK] / R50NK for each
mouse and shown for three mice per group. (E) NR50 of KTSU versus KTCONT: Normalization of R50 values of KTs from mice treated
with sunitinib (KTSU) relative to the mean R50 values of KTs from control mice (KTCONT) calculated as [R50 KTSU − R50 KTmean cont] /
R50 KTmean cont for each mouse and shown for three mice per treatment group. (F) NR50 of NKSU versus NKCONT: Normalization of
R50 values of NKs of mice treated with sunitinib relative to the mean R50 values of NKs from control mice calculated as [R50 NKSU −
R50 NKmean cont] / R50 NKmean cont for each mouse and shown for three mice per treatment group. Data are presented for three mice
per treatment group from the same experiment shown in Figure 1.
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that NR50 of KTs relative to NKs were consistently much smaller
in SU20-treated mice in a range of 0.04 to 0.08 compared with a
wide range of 0.12 to 0.43 in SU10-treated, SU40-treated, or control
mice (Figure 2D). When NR50 was calculated as R50 values of KTs
from sunitinib-treated mice relative to KTs from control mice, NR50
of SU20-treated mice was consistently lower than that of SU40-treated
mice (Figure 2E). A trend to lower NR50 values was also observed with
SU10-treated mice (Figure 2E). To assess the effect of sunitinib on con-
tralateral NKs, R50 values ofNKs frommice treated with sunitinibwere
normalized to NKs from control mice (Figure 2F). These NR50 data of
NKs showed lower values for SU10- and SU20-treated mice compared
with SU40-treated mice (Figure 2F ).
DCE-MRI Analysis of Gd Kinetics of Uptake and
Clearance Using Parametric Color Maps
The parametric color maps from control mice showed accumulation
of Gd in the periphery of the tumor with no uptake in the core of
the tumor (Figure 3). In the NK of control mice, Gd uptake was dis-
tributed in the entire kidney with a higher uptake in the medullary
central area than in the peripheral cortex, probably reflecting nor-
mal secretion of contrast agent (Figure 3). The negative slope image
(Nslope) represents the clearance kinetics of Gd and shows low levels
in control mice. The kidneys of SU40-treated mice showed a strong
accumulation of Gd in most of the KTwith persisting high levels in
the peak, slope, and washout slope images (Figure 3). This effect was
also observed in the NK with increased levels of Gd in both cortex
and medulla, indicating that this high dosage of sunitinib also alters
the perfusion of NK tissue. Parametric color maps of SU20-treated mice
showed a significant accumulation of Gd in the KT including Gd up-
take in the tumor (Figure 3). These levels were high in the peak, slope,
and Nslope images. Similar findings were observed in NK treated with
SU20 (Figure 3). In contrast, KTs from SU10-treated mice showed no
uptake of Gd in the core of the tumor, but some was seen at its periphery
similar to KTs from control mice (Figure 3). Low levels were observed in
the peak, slope, andNslope images. The NK of mice treated with SU10
showed more Gd in the medulla than in the cortex (Figure 3) as seen in
NK of control mice. These findings were consistently observed in two
additional mice per group.
Therapeutic Response of KTs to Sunitinib
Previous studies using sunitinib in mouse tumor models have
demonstrated that dosages of 40 or 80 mg/kg per day were optimal
and biologically active, leading to tumor inhibition and inhibition of
phosphorylation of RTKs on cancer cells and endothelial cells [7–9].
Therefore, for our initial studies, we selected to test an optimal dosage
of 40 mg/kg per day of sunitinib to investigate the therapeutic response
of KTs using our KCI-18 RCC model. After intrarenal injection of
KCI-18 cells, by days 10 to 12, mice developed established KTs
Figure 3. DCE-MRI of KTs: Parametric color maps. Parametric color maps were constructed based on uptake and concentration of Gd in
the tissue, represented by the colors blue, green, yellow, and red with gradual increase of Gd from lowest values (blue) to highest values
(red). Data are presented for the same representative mouse from each treatment group shown in Figure 1. The KT is on the left, and the
contralateral NK is on the right of the MR images. The color coding in the kidneys are shown for IAUC, the peak, and the slope of C (t).
The Nslope represents the clearance of Gd after reaching the peak in the tissue.
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with a mean (SD) volume of 150 (7) mm3 and mean (SD) weight of
186 (4) mg compared with NK volume of 125 (2) mm3 and weight of
148 (12) mg. At that time point, mice were treated daily with 40mg/kg
per day of sunitinib. On day 28 after cell injection, the right KTand the
left NK were weighed (Figure 4A). On average, KTs in control animals
were 822 mg heavier than the contralateral NK. After sunitinib treat-
ment, KTs were significantly smaller compared with control mice (P =
.0001; Figure 4A). On average, SU40-treated tumors were 75% smaller
than tumors in control mice but were still significantly larger compared
with the contralateral NKs, with a mean (SD) difference of 209 (105)
mg (P < .0001; Figure 4A, inset). The weight disparity between the
tumor-bearing and the NK was significantly smaller in mice treated
with SU40 compared with control animals (P = .0002). By gross ob-
servation, control mice showed very large and extremely vascularized
tumors that invaded the entire kidney and grew into the abdominal
cavity (Figure 4A, inset). After sunitinib treatment, the shape of the
kidney was preserved in KTs indicating that SU40 therapy controlled
the growth and invasion of the tumor through kidney tissue, but the
kidneys looked ischemic.
DCE-MRI findings suggest that lower doses of sunitinib have a dif-
ferent effect on tumor perfusion; therefore, in additional separate
experiments, a dose-response study of sunitinib was tested, and a rep-
resentative experiment is presented in Figure 4B. The therapeutic
efficacy of lower dosages of 10 or 20 mg/kg per day of sunitinib was
evaluated and compared with that of 40 mg/kg per day. SU10 did not
significantly control KT growth (P = .43); tumors were only 25%
smaller than control tumors on average (Figure 4B) and appeared more
hemorrhagic by gross observation. Both SU20 and SU40 significantly
inhibited KT growth; average growth inhibition was 57% and 66%,
respectively, relative to control tumors (P = .003 and P = .0007, re-
spectively; Figure 4B). On average, tumors of SU20-treated mice were
43% smaller than tumors of SU10-treated mice, but the difference is
only marginally significant (P = .05). Although the tumors of SU40-
treated mice were not significantly smaller than those of SU20-treated
mice (P = .55), the variation in tumor size from mouse to mouse was
smaller in SU40-treated mice (Figure 4B). The extent of tumor growth
inhibition mediated by SU40 was comparable in these two series of
independent experiments presented in Figure 4, A and B, confirming
reproducibility of our findings.
Effect of Sunitinib on the Vasculature of KTs
For histologic studies, KT sections were stained with H&E or by
immunostaining with anti-CD31 Ab for the detection of blood vessels.
KTs presented as high-grade carcinomas, consisting of tumor cells with
large pleomorphic nuclei, prominent nucleoli, abundant eosinophilic
cytoplasm, and large cytoplasmic inclusions (Figure 5A, Control ) [34].
These tumors were highly vascularized with a sinusoidal vascular pattern
and abnormal enlarged vessels as seen both by H&E staining and anti-
CD31 staining (Figure 5, A and B, Control). Tumors treated with SU40
showed areas of tumor destruction and necrosis associated with hem-
orrhages but also remaining areas of viable tumor cells (Figure 5A).
The destruction of tumor vasculature was confirmed by anti-CD31
staining with disruption of the vessel walls, release of red blood cells
in the tumor, and minimal staining of endothelial cells by anti-CD31
(Figure 5B). KTs treated with SU20 clearly showed more regularized
and thinner vessels by H&E, and staining of endothelial cells in the
vessel walls by anti-CD31 (Figure 5,A and B) in contrast to the enlarged
abnormal vessels observed in KTs from control mice. However, tumors
treated with SU10 still contained enlarged abnormal vessels as con-
firmed by anti-CD31 staining (Figure 5, A and B), and some of them
were comparable to those observed in control mice.
Effect of Sunitinib on Vasculature of NK Tissue
Histologic analysis of NKs obtained from control mice showed
multiple regular and thin vessels by H&E (Figure 6A) and clear struc-
tures of vessels delineated by anti-CD31 staining of endothelial cells in
vessel walls (Figure 6B). In contrast, NKs obtained from mice treated
with the high SU40 dosage showed dilatation of blood vessels as seen by
H&E (Figure 6A). Some enlarged vessels showed disruption of vessel
walls as observed by anti-CD31 staining (Figure 6B). The effect of
SU20 on normal vessels in NKs was mild and caused dilatation only
in a few vessels, whereas most looked normal as seen by anti-CD31
staining, in contrast to the numerous vessels enlarged by SU40 treat-
ment (Figure 6, A and B). No effect on vessels in the NK was observed
Figure 4. KCI-18 KT response to sunitinib. Mice bearing established
KTs were treated daily with sunitinib for 18 days, then tumors were
resected and weighted. (A) Response to optimal dose of sunitinib.
The kidney weights and their median are reported for 10 mice per
group treated with vehicle (control) or sunitinib at 40 mg/kg per day
(SU40) compared with the contralateral NK weights in each ex-
perimental group. Inset contains pictures of KTs of control mice or
SU40-treatedmice comparedwith NKs. (B) Sunitinib dose-response.
The kidney weights and their median are reported for eight mice
per group treated with vehicle (control) or sunitinib at dosages of
40, 20, or 10mg/kg per day (SU40, SU20, or SU10, respectively) com-
pared with the contralateral NK weights in each experimental group.
*P < .05. Data presented were obtained from separate representa-
tive experiments.
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with SU10; the vessels looked thin and regular and were comparable to
those seen inNKs of controlmice (Figure 6,A andB). It should be noted
that although disruptions in normal vessels were observed after sunitinib
therapy, themice treatedwith dosages of 20 to 40mg/kg per day showed
no apparent signs of drug toxicity.
Direct Cytotoxic Effect of Sunitinib and Expression of
VEGFR-2 and PDGFR-β on KCI-18 Cells and KTs
To determine whether sunitinib has a direct cytotoxic effect on
KCI-18 RCC, cells were treated in vitro with various doses and plated
in colony formation assay [37]. Compared with control cells treated
with vehicle, a significant dose-dependent effect was observed at doses
Figure 5. Histologic diagnosis of KCI-18 KTs treated with various
dosages of sunitinib. KTs resected from mice for the experiments
described in Figure 4 were processed for histologic diagnosis, and
tumor sections were stained either with H&E (A) or with anti-CD31
immunostaining (B).H indicates hemorrhages;N, necrosis; T, tumor;
V, vessels. Control untreated tumors consisted of tumor cells with
large pleomorphic nuclei and were highly vascularized with a sinu-
soidal vascular pattern and abnormal enlarged vessels. Tumors
treated with SU40 showed areas of tumor destruction and necrosis
associated with hemorrhages and areas of viable tumor cells. Tumor
sections stained with anti-CD31 reveal destruction of tumor vascula-
ture anddisruption of the vesselwalls. KTs treatedwith SU20 showed
more regularized and thinner vessels both by H&E and by anti-CD31
staining. SU10-treated tumors show enlarged abnormal vessels as
confirmed by anti-CD31 staining with staining of areas of endothelial
cells lining vessel walls. Original magnifications, ×40.
Figure 6. Histologic diagnosis of NKs frommice treatedwith various
doses of sunitinib. The contralateral left NKs (not bearing a tumor)
resected from mice of the experiments described in Figure 4 were
processed for histologic diagnosis, and kidney tissue sections
were stained either with H&E (A) or with anti-CD31 immunostaining
(B). NKs obtained fromcontrolmice showedmultiple regular and thin
vessels (V) by H&E and clear structures of vessels delineated by anti-
CD31 staining of endothelial cells in vessel walls. After high SU40
dosage, dilatation of blood vessels was observed as seen by H&E.
Enlarged vessels sometimes showed disruption of vessel walls seen
by anti-CD31 staining. Themilder effect of SU20 onnormal vessels in
NKs caused dilatation only in a few vessels, whereas most looked
normal as seen by anti-CD31 staining. No effect on vessels in the
NK was observed with SU10; the vessels looked thin and regular.
Original magnifications, ×40.
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greater than 0.5 μMwith 40% inhibition in survival at 1 μMand com-
plete cell killing at 2.5 to 5 μM (P < .05; Figure 7A).
The effect of sunitinib on expression of RTKs targets, VEGFR-2
and PDGFR-β, was determined by Western blot analysis of cultured
cells and KTs. Both VEGFR-2 and PDGFR-β receptors showed a high
expression on KCI-18 cells cultured in vitro (Figure 7B), confirming
that our KCI-18 RCC cell line expresses these receptors. KTs obtained
frommice treated with various doses of sunitinib for 7 days in vivowere
also tested for expression of RTKs. Both VEGFR-2 and PDGFR-β re-
ceptors were strongly expressed by KCI-18 KTs in control mice (Fig-
ure 7C). A trend to increased expression of VEGFR-2 and PDGFR-β
was observed after treatment with a low dosage of SU10 (Figure 7C).
At higher dosages of SU20 and SU40, a trend to decreased expression
of VEGFR-2 and PDGFR-β receptors was observed (Figure 7C). Inter-
estingly, modulation of VEGFR-2 and PDGFR-β receptors was also
observed in NKs, with increased expression in SU10-treated mice and
lower expression in SU20-treated mice (Figure 7C ).
Discussion
To design novel targeted therapies for metastatic RCC, extensive
research is ongoing to test drugs that target both the tumor cells and the
tumor vasculature to inhibit processes that stimulate tumor growth in
the tumor microenvironment. Antiangiogenic therapy causing excessive
vascular regression could compromise the delivery of drugs or oxygen
in the tumor when combined with conventional cytotoxic therapies
[21,22]. Using a preclinical RCC model, we have investigated, by
DCE-MRI, vascular changes in KTs induced by the antiangiogenic
drug sunitinib to select doses that could induce transient vessel normali-
zation by pruning inefficient blood vessels and thereby improve tumor
blood flow and subsequent drug delivery to tumor cells by chemo-
therapy [25–27,39].
A dose-dependent therapeutic efficacy of sunitinib for KCI-18 RCC
tumor xenografts was demonstrated with dosages of 20 and 40 mg/kg
per day, causing a significant inhibition/arrest of tumor growth and
limited invasion of the kidney by tumor cells, in agreement with pre-
vious preclinical animal studies [7–13]. Sunitinib exerted a direct cyto-
toxic effect at doses greater than 0.5 μM in KCI-18 cells in vitro. As
documented in clear cell RCC and papillary RCC human tumor speci-
mens [13,40], we found that KCI-18 cells and tumors also expressed
the VEGFR-2 and PDGFR-β RTKs targets of sunitinib. Increasing
doses of sunitinib caused a lower expression of these receptors on
KTs, probably due to the modulation of these receptors. These find-
ings suggest that sunitinib could inhibit KCI-18 tumor growth through
targeting of RTKs signaling on tumor cells and/or on endothelial cells
or stromal cells resulting in direct antitumor and antiangiogenic activi-
ties as shown in other studies [7]. Interestingly, modulation of RTKs
receptors by sunitinib was also observed on NK tissues, confirming
the effect of the drug on the vasculature of normal tissues. In agree-
ment with our findings, recent animal studies [41] and clinical trials
of sunitinib for metastatic RCC or breast cancer reported decreased
soluble VEGFRs’ plasma levels [42,43], which suggested modulation
of VEGF pathway biomarkers by sunitinib. Furthermore, previous
pharmacokinetic studies in mouse xenograft models demonstrated
plasma levels of 50 to 100 ng/ml for 12 hours when mice were treated
with the same efficacious dosages of 20 to 40mg/kg per day of sunitinib
as used in our studies, resulting in the inhibition of VEGFR-2 and
PDGFR-β RTKs [7]. Comparable plasma levels of 50 to 100 ng/ml
of sunitinib were also measured in pharmacokinetic studies of patients
receiving 50-mg daily doses [44].
Figure 7. Survival fraction of KCI-18 cells treated with sunitinib and expression of VEGFR-2 and PDGFR-β sunitinib targets on cells and
tumors. (A) Inhibition of cell growth in vitro. KCI-18 cells were treated with sunitinib doses of 0.1 to 5 μM and plated in a colony formation
assay for 10 days. Bars represent the mean survival fraction ± SEM of triplicate wells. (B and C) Expression of VEGFR-2 and PDGFR-β on
KCI-18 cells and tumors. KCI-18 cells or KTs were lysed, and protein extracts were first immunoprecipitated with anti–VEGFR-2 or anti–
PDGFR-β Abs. Immune complexes were separated using protein A agarose beads, and the expression of VEGFR-2 and PDGFR-β was
determined by Western blot analysis. (B) Expression of VEGFR-2 or anti–PDGFR-β on KCI-18 cells. (C) Expression of VEGFR-2 or PDGFR-β
in KCI-18 KTs and NKs from mice treated with SU10, SU20, or SU40 compared with control (Con) mice.
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Sunitinib also induced dose-dependent vascular changes, which were
observed both in KTs and in NK tissues by DCE-MRI. In control
mice, the clearance of Gd in the KT was slow compared with faster
clearance in the NK, probably as a result of leakiness from the abnormal
enlarged tumor vessels observed histologically. Parametric maps from
control mice showed accumulation of Gd in the periphery of the tumor
with no uptake in the core of the tumor, indicative of poor vascularity
and perfusion in the core of the tumor as shown in other MRI studies
of xenograft tumors [32,33]. In contrast, the NK of control mice
showed distribution of Gd in the entire kidney with lower uptake in
the peripheral cortex and a higher uptake in the medulla probably
due to greater numbers of vessels in that area and reflecting normal
secretion of contrast agent. Compared with control tumors, KTs from
mice treated with a low dosage of 10 mg/kg per day of sunitinib showed
mild changes in Gd uptake and clearance kinetics of KTs. These SU10-
treated tumors had also poor tumor perfusion in the core of the tumor
and histologically showed enlarged abnormal vessels similar to findings
observed in control tumors. Likewise, SU10 caused minimal effect on
NK tissue vasculature with no changes in vascular permeability or vessel
morphology compared with control mice.
A therapeutic high dosage of 40 mg/kg per day induced vascular
permeability changes resulting in retention of Gd in both left and
right kidneys. Gd retention was greater in the KT than in the NK. This
increased vascular permeability of Gd in the tumor could be due to
the damaged vasculature and leakage of Gd into surrounding kidney
tissue with slow kinetics of washout. Histologic studies confirmed
destruction of tumor vasculature of SU40-treated KTs and disrup-
tion of the vessel walls causing hemorrhages. It should be noted that
increased levels of Gd were also observed in both cortex and medulla
of NKs, indicating that this high SU40 dosage alters the kinetics of
uptake and contrast clearance of NK tissue. These data are supported
by histologic observation of dilatation and disruption of normal vessels
detected by anti-CD31 Ab staining of NK tissue. We conclude that
the dosage of 40 mg/kg per day of sunitinib causes excessive vascular
damage and vascular permeability in KTs and alterations of NK ves-
sels. This in turn suggests that this dosage is not appropriate for combi-
nation chemotherapies.
After treatment with an intermediate sunitinib dosage of 20 mg/kg
per day, improved Gd clearance was observed with less Gd retention
than that seen with SU40 or in control mice. Interestingly, in SU20-
treated mice, Gd uptake and clearance in the C (t) curves, IAUC, and
CIAUC showed identical patterns in the KT compared with the NK
as confirmed by the low R50 value of KTs relative to the R50 value of
NKs (Figure 2D). A clear shift to the left of IAUC curves of SU20-
treated mice was observed compared with control mice and SU40-
treated mice as shown also by the low R50 value of KTs treated with
SU20 relative to the R50 value of control KTs (Figure 2E). These data
suggest a return to more “normal vasculature” with lower permeability
(i.e., less leaky vessels) after treatment with SU20. Interestingly, a similar
pattern was observed in NKs of mice treated with sunitinib compared
with those of controlmice showingNR50 values lower for SU20-treated
mice than for SU40-treated mice, indicating a milder effect of SU20
dosage on vasculature of NK tissue (Figure 2F ). Parametric maps re-
vealed increased Gd uptake in the core of the tumor and surrounding
kidney tissue in SU20-treated mice. Histologically, the vessels of KTs
treated with SU20 clearly showed more regularized and thinner vessels,
indicating pruning or normalization of tumor vessels compared with the
enlarged vessels of control KTs. The effect of SU20 on vessels in NKs
was mild and caused dilatation only in a few vessels.
In summary, imaging of tumor vasculature changes by DCE-MRI
and histologic diagnosis indicates that a lower dosage of 20 mg/kg
per day of sunitinib could cause “pruning” or normalization of the
tumor vasculature allowing for better tumor perfusion and decreased
leakiness of vessels. Moreover, this dosage caused only mild vascular
changes in normal tissues and thus could be less toxic to normal vessels,
suggesting that this dosage could be used for combination with chemo-
therapy or radiotherapy.
Our histologically verified studies demonstrate that the use of DCE-
MRI is a useful means for monitoring vascular changes induced by
sunitinib in both tumors and normal tissues. These data can be used
to select the dose and schedule of sunitinib and potentially other anti-
angiogenic drugs causing transient normalization of tumor vasculature
for combination therapies.
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